We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+4.64%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$106B
AUM Growth
+$2.27B
Cap. Flow
-$488M
Cap. Flow %
-0.46%
Top 10 Hldgs %
30.07%
Holding
4,478
New
179
Increased
2,056
Reduced
1,848
Closed
61

Top Buys

Rank Stock Value
1
XOM icon
ExxonMobil
XOM
+$101M
2
GEV icon
GE Vernova
GEV
+$75.4M
3
CRH icon
CRH
CRH
+$48.5M
4
CRWD icon
CrowdStrike
CRWD
+$45.8M
5
DELL icon
Dell
DELL
+$35.8M

Sector Composition

Rank Sector Weight
1 Technology 30.98%
2 Financials 12.55%
3 Healthcare 11.48%
4 Consumer Discretionary 10.52%
5 Industrials 8.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PUK icon
3001
Prudential
PUK
$35.2B
$213K ﹤0.01%
11,652
+201
+2% +$3.79K
SMLR
3002
DELISTED
Semler Scientific
SMLR
$213K ﹤0.01%
6,197
+1,320
+27% +$38K
AV
3003
DELISTED
Aviva Plc
AV
$212K ﹤0.01%
17,396
+4,956
+40% +$60.4K
ADVM
3004
DELISTED
Adverum Biotechnologies
ADVM
$211K ﹤0.01%
30,821
+30,528
+10,419% +$284K
BH icon
3005
Biglari Holdings Class B
BH
$1.21B
$211K ﹤0.01%
1,093
+11
+1% +$2.16K
BTMD icon
3006
Biote Corp
BTMD
$44.9M
$211K ﹤0.01%
28,225
+14,404
+104% +$88.8K
ASND icon
3007
Ascendis Pharma A/S
ASND
$16.8B
$209K ﹤0.01%
1,533
+143
+10% +$19.5K
VTYX
3008
DELISTED
Ventyx Biosciences
VTYX
$209K ﹤0.01%
90,331
+24,885
+38% +$103K
CVRX icon
3009
CVRx
CVRX
$63.4M
$207K ﹤0.01%
17,260
+3,863
+29% +$44.5K
FHTX icon
3010
Foghorn Therapeutics
FHTX
$360M
$206K ﹤0.01%
35,910
+9,171
+34% +$54.6K
DC icon
3011
Dakota Gold
DC
$804M
$206K ﹤0.01%
80,867
+11,926
+17% +$31.7K
USCB icon
3012
USCB Financial Holdings
USCB
$412M
$206K ﹤0.01%
16,063
-999
-6% -$11.6K
RIGL icon
3013
Rigel Pharmaceuticals
RIGL
$750M
$205K ﹤0.01%
25,000
+1,206
+5% +$12.6K
BYRN icon
3014
Byrna Technologies
BYRN
$101M
$205K ﹤0.01%
+20,577
New +$254K
EPOL icon
3015
iShares MSCI Poland ETF
EPOL
$756M
$205K ﹤0.01%
8,364
-154,976
-95% -$3.76M
NWFL icon
3016
Norwood Financial Corp
NWFL
$368M
$205K ﹤0.01%
8,073
-312
-4% -$7.72K
CRBU icon
3017
Caribou Biosciences
CRBU
$164M
$205K ﹤0.01%
124,915
+2,398
+2% +$7.66K
RELL icon
3018
Richardson Electronics
RELL
$304M
$205K ﹤0.01%
17,206
+2,803
+19% +$29.9K
GWRS icon
3019
Global Water Resources
GWRS
$219M
$204K ﹤0.01%
16,880
-510
-3% -$6.36K
KG
3020
Kestrel Group
KG
$69M
$204K ﹤0.01%
4,952
+10
+0.2% +$422
MCHI icon
3021
iShares MSCI China ETF
MCHI
$6.38B
$203K ﹤0.01%
4,820
MYFW icon
3022
First Western Financial
MYFW
$306M
$203K ﹤0.01%
11,949
-350
-3% -$5.74K
TE
3023
T1 Energy
TE
$1.63B
$203K ﹤0.01%
+119,430
New +$228K
SEZL
3024
Sezzle
SEZL
$3.97B
$203K ﹤0.01%
+13,806
New +$161K
CSAN icon
3025
Cosan
CSAN
$2.84B
$202K ﹤0.01%
20,777
-8,595
-29% -$93.1K

Similar funds

RhumbLine Advisers's Q2 2024 Portfolio in Review

As of Q2 2024, RhumbLine Advisers held 4,478 positions worth $106B, up 2.2% from $104B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

RhumbLine Advisers's Q2 2024 filing shows 179 new, 2,056 increased, 1,848 reduced and 61 closed positions. Its largest new stake was GE Vernova: 475,685 shares worth $81.6M. The largest sale was iShares Russell 1000 ETF, an estimated $180M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 28% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q2 2024 buy was GE Vernova: 475,685 shares worth $81.6M.
  • RhumbLine Advisers added most to ExxonMobil in Q2 2024, an estimated $101M increase.
  • RhumbLine Advisers's biggest Q2 2024 reduction was iShares Russell 1000 ETF, cutting an estimated $180M.
  • RhumbLine Advisers fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $121M.
  • RhumbLine Advisers's ten largest holdings make up 30% of its $106B portfolio in Q2 2024.
  • RhumbLine Advisers opened 179 new positions and closed 61 in Q2 2024.
  • RhumbLine Advisers's portfolio value rose 2.2% quarter-over-quarter to $106B.

Based on RhumbLine Advisers's 13F filing for Q2 2024, filed 1 Aug 2024.